In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Roche licenses Plexxikon's Phase I kidney disease candidate

Executive Summary

Continuing a relationship that began two years ago, a new agreement has Roche licensing exclusive worldwide development and commercialization rights to Plexxikon Inc.'s (small-molecule therapeutics) Phase I Raf kinase inhibitor PLX5568 for polycystic kidney disease (PKD), an inherited condition characterized by the formation of renal cysts, which if enlarged, infected, or ruptured, could result in potential kidney failure. There is currently no marketed treatment for PKD.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies